Toll-like receptors: A new target in rheumatoid arthritis?

Expert Review of Clinical Immunology

Volumn 2, Issue 4, 2006, Pages 585-599

  Drexler, Stefan K ^a   Sacre, Sandra M ^a   Foxwell, Brian M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; ADALIMUMAB; BORTEZOMIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6 ANTIBODY; MATRIX METALLOPROTEINASE; METHOTREXATE; MYELOID DIFFERENTIATION FACTOR 88; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; SCLEROPROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; CELL DAMAGE; CHRONIC INFLAMMATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DRUG DESIGN; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; INNATE IMMUNITY; LUPUS LIKE SYNDROME; MULTIPLE MYELOMA; NECROSIS; NONHUMAN; OSTEOPOROSIS; PREVALENCE; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIAL FLUID;

EID: 33748480691     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.4.585     Document Type: Review

References (218)

1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344(12), 907-916 (2001).
2. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 85(3), 307-310 (1996).
3. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The arthritis and rheumatism council low-dose glucocorticoid study group. N. Engl. J. Med. 333(3), 142-146 (1995).
4. Furst DE. The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis. Clin. Exp. Rheumatol. 17(1), 39-40 (1999).
5. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930), 1105-1110. (1994).
6. Feldmann M, Maini RN. Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Ann. Rev. Immunol. 19, 163-196 (2001).
7. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130(6), 478-486 (1999).
8. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48(1), 35-45 (2003).
9. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41(12), 2196-2204 (1998).
10. Campion Gv, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. 39(7), 1092-1101 (1996).
11. Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50(6), 1761-1769 (2004).
12. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann. Rev. Immunol. 7, 445-480 (1989).
13. Sacre SM, Andreakos E, Taylor P, Feldmann M, Foxwell BM. Molecular therapeutic targets in rheumatoid arthritis. Expert Rev. Mol. Med. 7(16), 1-20 (2005).
14. Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349(20), 1907-1915 (2003).
15. Kremer JM, Dougados M, Emery P et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52(8), 2263-2271 (2005).
16. Ruderman EM, Pope RM. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 7(Suppl. 2), S21-S25 (2005).
17. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345(15), 1098-1104. (2001).
18. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum. 39(5), 732-735 (1996).
19. Krause A, Kamradt T, Burmester GR. Potential infectious agents in the induction of arthritides. Curr. Opin. Rheumatol. 8(3), 203-209 (1996).
20. Silman AJ, MacGregor AJ, Thomson W et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br. J. Rheumatol. 32(10), 903-907 (1993).
21. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N. Engl. J. Med. 298(16), 869-871 (1978).
22. Corrigall VM, Panayi GS. Autoantigens and immune pathways in rheumatoid arthritis. Crit. Rev. Immunol. 22(4), 281-293 (2002).
23. Vos K, Steenbakkers P, Miltenburg AM et al. Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. 59(7), 544-548 (2000).
24. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416(6881), 603-607 (2002).
25. Halfon MS, Keshishian H. The Toll pathway is required in the epidermis for muscle development in the Drosophila embryo. Dev. Biol. 199(1), 164-174 (1998).
26. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86(6), 973-983 (1996).
27. Radstake TR, Roelofs MF, Jenniskens YM et al. Expression of Toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-γ. Arthritis Rheum. 50(12), 3856-3865 (2004).
28. Seibl R, Birchler T, Loeliger S et al. Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am. J. Pathol. 162(4), 1221-1227 (2003).
29. + blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum. 50(5), 1457-1467 (2004).
30. Kawai T, Akira S. TLR signaling. Cell. Death Differ. 13(5), 816-825 (2006).
31. Takeda K, Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17(1), 1-14 (2005).
32. Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 7(6), 837-847 (1997).
33. Burns K, Martinon F, Esslinger C et al. MyD88, an adapter protein involved in interleukin-1 signaling. J. Biol. Chem. 273(20), 12203-12209 (1998).
34. Zhang FX, Kirschning CJ, Mancinelli R et al. Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J. Biol. Chem. 274(12), 7611-7614 (1999).
35. Muzio M, Ni J, Feng P, Dixit VM. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278(5343), 1612-1615 (1997).
36. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110(2), 191-202 (2002).
37. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28(4), 197-208 (1998).
38. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11(1), 115-122 (1999).
39. Fitzgerald KA, Palsson-McDermott EM, Bowie AG et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413(6851), 78-83 (2001).
40. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat. Immunol. 2(9), 835-841 (2001).
41. Yamamoto M, Sato S, Mori K et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J. Immunol. 169(12), 6668-6672 (2002).
42. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat. Immunol. 4(2), 161-167 (2003).
43. Fitzgerald KA, Rowe DC, Barnes BJ et al. LPS-TLR4 signaling to IRF-3/7 and NF-{kappa}B involves the Toll adapters TRAM and TRIF. J. Exp. Med. 198(7), 1043-1055 (2003).
44. Oshiumi H, Sasai M, Shida K, Fujita T, Matsumoto M, Seya T. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to Toll-like receptor 4 TICAM-1 that induces interferon-β. J. Biol. Chem. 278(50), 49751-49762 (2003).
45. Hacker H, Redecke V, Blagoev B et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439(7073), 204-207 (2006).
46. Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4(7), 499-511 (2004).
47. Kawai T, Takeuchi O, Fujita T et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 167(10), 5887-5894 (2001).
48. Takaoka A, Yanai H, Kondo S et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434(7030), 243-249 (2005).
49. Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA. Rip1 mediates the Trif-dependent Toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J. Biol. Chem. 280(44), 36560-36566 (2005).
50. Covert MW, Leung TH, Gaston JE, Baltimore D. Achieving stability of lipopolysaccharide-induced NF-κB activation. Science 309(5742), 1854-1857 (2005).
51. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 76(3), 514-519 (2004).
52. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol. Rev. 204, 27-42 (2005).
53. Sacre SM, Drexler SK, Foxwell BM. Toll-like receptors and rheumatoid arthritis: is there a connection? In: Toll-like Receptors in Inflammation. O'Neill LAJ, Brint E (Eds), Birkhauser, Basel, Switzerland, 19-40 (2005).
54. Brentano F, Kyburz D, Schorr O, Gay R, Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol. 233(2), 90-96 (2005).
55. Searle J, Kerr JF, Bishop CJ. Necrosis and apoptosis: distinct modes of cell death with fundamentally different significance. Pathol. Ann. 17(Pt 2), 229-259 (1982).
56. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell. Biol. 16(6), 663-669 (2004).
57. Platt N, da Silva RP, Gordon S. Recognizing death: the phagocytosis of apoptotic cells. Trends Cell Biol. 8(9), 365-372 (1998).
58. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191(3), 423-434 (2000).
59. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5(11), 1249-1255 (1999).
60. Vollmer J, Tluk S, Schmitz C et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202(11), 1575-1585 (2005).
61. Vabulas RM, Ahmad-Nejad P, da Costa C et al. Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem. 276(33), 31332-31339 (2001).
62. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J. Biol. Chem. 277(17), 15107-15112 (2002).
63. Vabulas RM, Braedel S, Hilf N et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J. Biol. Chem. 277(23), 20847-20853 (2002).
64. Roelofs MF, Boelens WC, Joosten LA et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J. Immunol. 176(11), 7021-7027 (2006).
65. Wallin RP, Lundqvist A, More SH, von Bonin A, Kiessling R, Ljunggren HG. Heat-shock proteins as activators of the innate immune system. Trends Immunol. 23(3), 130-135 (2002).
66. Gao B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor α release by murine macrophages. J. Biol. Chem. 278(1), 174-179 (2003).
67. Bausinger H, Lipsker D, Ziylan U et al. Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur. J. Immunol. 32(12), 3708-3713 (2002).
68. Reed RC, Berwin B, Baker JP, Nicchitta CV. GRP94/gp96 elicits ERK activation in murine macrophages. A role for endotoxin contamination in NF-κB activation and nitric oxide production. J. Biol. Chem. 278(34), 31853-31860 (2003).
69. Liu B, Dai J, Zheng H, Stoilova D, Sun S, Li Z. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc. Natl Acad. Sci. USA 100(26), 15824-15829 (2003).
70. + T cell Th1 cytokine production in vivo. J. Immunol. 172(7), 4195-4203 (2004).
71. Andersson U, Wang H, Palmblad K et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192(4), 565-570 (2000).
72. Fiuza C, Bustin M, Talwar S et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101(7), 2652-2660 (2003).
73. Park JS, Arcaroli J, Yum HK et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am. J. Physiol. Cell Physiol. 284(4), C870-C879 (2003).
74. Park JS, Svetkauskaite D, He Q et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279(9), 7370-7377 (2004).
75. Park JS, Gamboni-Robertson F, He Q et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290(3), C917-C924 (2006).
76. Yanagishita M, Hascall VC. Cell surface heparan sulfate proteoglycans. J. Biol. Chem. 267(14), 9451-9454 (1992).
77. Kainulainen V, Wang H, Schick C, Bernfield M. Syndecans, heparan sulfate proteoglycans maintain the proteolytic balance of acute wound fluids. J. Biol. Chem. 273(19), 11563-11569 (1998).
78. Lohmander LS, Dahlberg L, Ryd L, Heinegard D. Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum. 32(11), 1434-1442 (1989).
79. Oragui EE, Nadel S, Kyd P, Levin M. Increased excretion of urinary glycosaminoglycans in meningococcal septicemia and their relationship to proteinuria. Crit. Care Med. 28(8), 3002-3008 (2000).
80. Weigel PH, Fuller GM, LeBoeuf RD. A model for the role of hyaluronic acid and fibrin in the early events during the inflammatory response and wound healing. J. Theor. Biol. 119(2), 219-234 (1986).
81. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J. Immunol. 168(10), 5233-5239 (2002).
82. Termeer C, Benedix F, Sleeman J et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J. Exp. Med. 195(1), 99-111 (2002).
83. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J. Biol. Chem. 279(17), 17079-17084 (2004).
84. Schaefer L, Babelova A, Kiss E et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 115(8), 2223-2233 (2005).
85. Jarnagin WR, Rockey DC, Koteliansky VE, Wang SS, Bissell DM. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J. Cell Biol. 127(6 Pt 2), 2037-2048 (1994).
86. George J, Wang SS, Sevcsik AM et al. Transforming growth factor-β initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. Am. J. Pathol. 156(1), 115-124 (2000).
87. Saito S, Yamaji N, Yasunaga K et al. The fibronectin extra domain A activates matrix metalloproteinase gene expression by an interleukin-1-dependent mechanism. J. Biol. Chem. 274(43), 30756-30763 (1999).
88. Hino K, Shiozawa S, Kuroki Y et al. EDA-containing fibronectin is synthesized from rheumatoid synovial fibroblast-like cells. Arthritis Rheum. 38(5), 678-683 (1995).
89. Okamura Y, Watari M, Jerud ES et al. The extra domain A of fibronectin activates Toll-like receptor 4. J. Biol. Chem. 276(13), 10229-10233 (2001).
90. Dvorak HN, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 227(4690), 1059-1061 (1985).
91. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J. Immunol. 167(5), 2887-2894 (2001).
92. Biragyn A, Ruffini PA, Leifer CA et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 298(5595), 1025-1029 (2002).
93. Yang D, Chertov O, Bykovskaia SN et al. β-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286(5439), 525-528 (1999).
94. Biragyn A, Surenhu M, Yang D et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 167(11), 6644-6653 (2001).
95. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279(13), 12542-12550 (2004).
96. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303(5663), 1526-1529 (2004).
97. Panet A. Regulation of the antiviral and anticellular activities of interferon by exogenous double-stranded RNA. Mol. Cell Biochem. 52(2), 153-160 (1983).
98. Lau CM, Broughton C, Tabor AS et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202(9), 1171-1177 (2005).
99. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374(6522), 546-549 (1995).
100. Richardson B. Impact of aging on DNA methylation. Ageing Res. Rev. 2(3), 245-261 (2003).
101. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33(11), 1665-1673 (1990).
102. Sun S, Beard C, Jaenisch R, Jones P, Sprent J. Mitogenicity of DNA from different organisms for murine B cells. J. Immunol. 159(7), 3119-3125 (1997).
103. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 118(2), 229-241 (2004).
104. Jiang D, Liang J, Fan J et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 11(11), 1173-1179 (2005).
105. van der Heijden IM, Wilbrink B, Tchetverikov I et al. Presence of bacterial DNA and bacterial peptidoglycans in joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum. 43(3), 593-598 (2000).
106. Schumacher HR Jr, Arayssi T, Crane M et al. Chlamydia trachomatis nucleic acids can be found in the synovium of some asymptomatic subjects. Arthritis Rheum. 42(6), 1281-1284 (1999).
107. Gerard HC, Wang Z, Wang GF et al. Chromosomal DNA from a variety of bacterial species is present in synovial tissue from patients with various forms of arthritis. Arthritis Rheum. 44(7), 1689-1697 (2001).
108. Kempsell KE, Cox CJ, Hurle M et al. Reverse transcriptase-PCR analysis of bacterial rRNA for detection and characterization of bacterial species in arthritis synovial tissue. Infect. Immun. 68(10), 6012-6026 (2000).
109. Chen T, Rimpilainen M, Luukkainen R et al. Bacterial components in the synovial tissue of patients with advanced rheumatoid arthritis or osteoarthritis: analysis with gas chromatography-mass spectrometry and pan-bacterial polymerase chain reaction. Arthritis Rheum. 49(3), 328-334 (2003).
110. Schett G, Redlich K, Xu Q et al. Enhanced expression of heat shock protein 70 (HSP70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue. Differential regulation of HSP70 expression and HSF1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and antiinflammatory drugs. J. Clin. Invest. 102(2), 302-311 (1998).
111. Scott DL, Delamere JP, Walton KW. The distribution of fibronectin in the pannus in rheumatoid arthritis. Br. J. Exp. Pathol. 62(4), 362-368 (1981).
112. Yu D, Rumore PM, Liu Q, Steinman CR. Soluble oligonucleosomal complexes in synovial fluid from inflamed joints. Arthritis Rheum. 40(4), 648-654 (1997).
113. Taniguchi N, Kawahara K, Yone K et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 48(4), 971-981 (2003).
114. Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang CH. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J. Exp. Med. 146(6), 1585-1602 (1977).
115. Joosten LA, Koenders MI, Smeets RL et al. Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J. Immunol. 171(11), 6145-6153 (2003).
116. Pieter M, Rethage J, Seibl R et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J. Immunol. 172(2), 1256-1265 (2004).
117. Liu ZQ, Deng GM, Foster S, Tarkowski A. Staphylococcal peptidoglycans induce arthritis. Arthritis Res. 3(6), 375-380 (2001).
118. Choe JY, Crann B, Wu SR, Corr M. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by Toll-like receptor 4 signaling. J. Exp. Med. 197(4), 537-542 (2003).
119. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 52(9), 2656-2665 (2005).
120. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S et al. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52(8), 2313-2322 (2005).
121. Kyburz D, Rethage J, Seibl R et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by Toll-like receptor signaling. Arthritis Rheum. 48(3), 642-650 (2003).
122. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285(5425), 248-251 (1999).
123. Kokkola R, Sundberg E, Ulfgren AK et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum. 46(10), 2598-2603 (2002).
124. Kilding R, Akil M, Till S et al. A biologically important single nucleotide polymorphism within the Toll-like receptor-4 gene is not associated with rheumatoid arthritis. Clin. Exp. Rheumatol. 21(3), 340-342 (2003).
125. Lamb RM, Zeggini E, Thomson W, Donn R. Toll-like receptor 4 (TLR4) gene polymorphisms and susceptibility to juvenile idiopathic arthritis. Ann. Rheum. Dis. 64(5), 767-769 (2004).
126. Sanchez E, Orozco G, Lopez-Nevot MA, Jimenez-Alonso J, Martin J. Polymorphisms of Toll-like receptor 2 and 4 genes in rheumatoid arthritis and systemic lupus erythematosus. Tissue Antigens 63(1), 54-57 (2004).
127. Radstake TR, Franke B, Hanssen S et al. The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum. 50(3), 999-1001 (2004).
128. Hong Z, Jiang Z, Liangxi W et al. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int. Immunopharmacol. 4(2), 223-234 (2004).
129. Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford) 45(6), 703-710 (2006).
130. Ogawa S, Lozach J, Benner C et al. Molecular determinants of crosstalk between nuclear receptors and Toll-like receptors. Cell 122(5), 707-721 (2005).
131. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of Toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5(6), 446-458 (2005).
132. Han J, Ulevitch RJ. Limiting inflammatory responses during activation of innate immunity. Nat. Immunol. 6(12), 1198-1205 (2005).
133. Kopp E, Medzhitov R, Carothers J et al. ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev. 13(16), 2059-2071 (1999).
134. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3(11), 1285-1289 (1997).
135. de Crombrugghe B, Lefebvre V, Behringer RR, Bi W, Murakami S, Huang W. Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol. 19(5), 389-394 (2000).
136. Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-α. J. Biol. Chem. 275(5), 3687-3692 (2000).
137. Asahara H, Asanuma M, Ogawa N, Nishibayashi S, Inoue H. High DNA-binding activity of transcription factor NF-κB in synovial membranes of patients with rheumatoid arthritis. Biochem. Mol. Biol. Int. 37(5), 827-832 (1995).
138. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-κB in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum. 38(12), 1762-1770 (1995).
139. Marok R, Winyard PG, Coumbe A et al. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum. 39(4), 583-591 (1996).
140. Foxwell B, Browne K, Bondeson J et al. Efficient adenoviral infection with IκBα reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF-κB dependent. Proc. Natl Acad. Sci. USA 95(14), 8211-8215 (1998).
141. Smith C, Andreakos E, Crawley JB, Brennan FM, Feldmann M, Foxwell BM. NF-κB-inducing kinase is dispensable for activation of NF-κB in inflammatory settings but essential for lymphotoxin β receptor activation of NF-κB in primary human fibroblasts. J Immunol. 167(10), 5895-5903 (2001).
142. Bondeson J, Foxwell B, Brennan F, Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc. Natl Acad. Sci. USA 96(10), 5668-5673 (1999).
143. Miagkov AV, Kovalenko DV, Brown CE et al. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl Acad. Sci. USA 95(23), 13859-13864 (1998).
144. Palombella VJ, Conner EM, Fuseler JW et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl Acad. Sci. USA 95(26), 15671-15676 (1998).
145. Tsao PW, Suzuki T, Totsuka R et al. The effect of dexamethasone on the expression of activated NF-κB in adjuvant arthritis. Clin. Immunol. Immunopathol. 83(2), 173-178 (1997).
146. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nature Rev. Drug Discov. 3(1), 17-26 (2004).
147. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS. Jun N-terminal kinase in rheumatoid arthritis. J. Pharmacol. Exp. Ther. 291(1), 124-130 (1999).
148. Schett G, Tohidast-Akrad M, Smolen JS et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 43(11), 2501-2512 (2000).
149. Dean JL, Brook M, Clark AR, Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J. Biol. Chem. 274(1), 264-269 (1999).
150. Ridley SH, Dean JL, Sarsfield SJ, Brook M, Clark AR, Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett. 439(1-2), 75-80 (1998).
151. Rutault K, Hazzalin CA, Mahadevan LC. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-α) mRNA induction. Evidence for selective destabilization of TNF-α transcripts. J. Biol. Chem. 276(9), 6666-6674. (2001).
152. Campbell J, Ciesielski CJ, Hunt AE et al. A novel mechanism for TNF-α regulation by p38 MAPK: involvement of NF-κB with implications for therapy in rheumatoid arthritis. J. Immunol. 173(11), 6928-6937 (2004).
153. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 279(3), 1453-1461 (1996).
154. Jackson JR, Bolognese B, Hillegass L et al. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J. Pharmacol. Exp. Ther. 284(2), 687-692 (1998).
155. Badger AM, Griswold DE, Kapadia R et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 43(1), 175-183 (2000).
156. Wadsworth SA, Cavender DE, Beers SA et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther. 291(2), 680-687 (1999).
157. McLay LM, Halley F, Souness JE et al. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg. Med. Chem. 9(2), 537-554 (2001).
158. Medvedev AE, Lentschat A, Kuhns DB et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198(4), 521-531 (2003).
159. Picard C, Puel A, Bonnet M et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299(5615), 2076-2079 (2003).
160. Kuhns DB, Long Priel DA, Gallin JI. Endotoxin and IL-1 hyporesponsiveness in a patient with recurrent bacterial infections. J. Immunol. 158(8), 3959-3964 (1997).
161. Hain R, Reif HJ, Krause E et al. Disease resistance results from foreign phytoalexin expression in a novel plant. Nature 361(6408), 153-156 (1993).
162. Hain R, Bieseler B, Kindl H, Schroder G, Stocker R. Expression of a stilbene synthase gene in Nicotiana tabacum results in synthesis of the phytoalexin resveratrol. Plant Mol. Biol. 15(2), 325-335 (1990).
163. Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Ann. NY Acad. Sci 957, 210-229 (2002).
164. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 17(14), 1975-1985 (2003).
165. Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J. Immunol. 175(5), 3339-3346 (2005).
166. Ahn JY, Choi IS, Shim JY et al. The immunomodulator ginsan induces resistance to experimental sepsis by inhibiting Toll-like receptor-mediated inflammatory signals. Eur. J. Immunol. 36(1), 37-45 (2006).
167. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221(4616), 1181-1183 (1983).
168. Asakura H, Aoshima K, Suga Y et al. Beneficial effect of the active form of vitamin D3 against LPS-induced DIC but not against tissue-factor-induced DIC in rat models. Thromb. Haemost. 85(2), 287-290 (2001).
169. Sadeghi K, Wessner B, Laggner U et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 36(2), 361-370 (2006).
170. Duramad O, Fearon KL, Chang B et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from
171. Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum. 50(5), 1686-1689 (2004).
172. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203(3), 553-561 (2006).
173. Barrat FJ, Meeker T, Gregorio J et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202(8), 1131-1139 (2005).
174. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199(12), 1631-1640 (2004).
175. Libby P. Inflammation in atherosclerosis. Nature 420(6917), 868-874 (2002).
176. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J. Biol. Chem. 276(20), 16683-16689 (2001).
177. Lee JY, Zhao L, Youn HS et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J. Biol. Chem. 279(17), 16971-16979 (2004).
178. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278(3), 1561-1568 (2003).
179. Walton KA, Hsieh X, Gharavi N et al. Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J. Biol. Chem. 278(32), 29661-29666 (2003).
180. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14(1), 141-147 (1994).
181. Michelsen KS, Wong MH, Shah PK et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl Acad. Sci. USA 101(29), 10679-10684 (2004).
182. Wright SD, Burton C, Hernandez M et al. Infectious agents are not necessary for murine atherogenesis. J. Exp. Med. 191(8), 1437-1442 (2000).
183. Bjorkbacka H, Kunjathoor VV, Moore KJ et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 10(4), 416-421 (2004).
184. Kirii H, Niwa T, Yamada Y et al. Lack of interleukin-1β decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 23(4), 656-660 (2003).
185. Elhage R, Jawien J, Rudling M et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 59(1), 234-240 (2003).
186. Nishina PM, Wang J, Toyofuku W, Kuypers FA, Ishida BY, Paigen B. Atherosclerosis and plasma and liver lipids in nine inbred strains of mice. Lipids 28(7), 599-605 (1993).
187. Kiechl S, Lorenz E, Reindl M et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347(3), 185-192 (2002).
188. Ameziane N, Beillat T, Verpillat P et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol. 23(12), e61-e64 (2003).
189. Roep BO. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes 45(9), 1147-1156 (1996).
190. Lang KS, Recher M, Junt T et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11(2), 138-145 (2005).
191. Hron JD, Peng SL. Type I IFN protects against murine lupus. J. Immunol. 173(3), 2134-2142 (2004).
192. Jingwu Z, Medaer R, Hashim GA, Chin Y, van den Berg-Loonen E, Raus JC. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann. Neurol. 32(3), 330-338 (1992).
193. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA, T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346(6280), 183-187 (1990).
194. Martin R, Voskuhl R, Flerlage M, McFarlin DE, McFarland HF. Myelin basic protein-specific T-cell responses in identical twins discordant or concordant for multiple sclerosis. Ann. Neurol. 34(4), 524-535 (1993).
195. Compston A, Coles A. Multiple sclerosis. Lancet 359(9313), 1221-1231 (2002).
196. Casetta I, Granieri E. Prognosis of multiple sclerosis: environmental factors. Neurol. Sci. 21(4 Suppl. 2), S839-S842 (2000).
197. Buljevac D, Flach HZ, Hop WC et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125(Pt 5), 952-960 (2002).
198. Waldner H, Collins M, Kuchroo VK. Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J. Clin. Invest. 113(7), 990-997 (2004).
199. Kerfoot SM, Long EM, Hickey MJ et al. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J. Immunol. 173(11), 7070-7077 (2004).
200. Linthicum DS. Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease. Immunobiology 162(3), 211-220 (1982).
201. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411(6837), 599-603 (2001).
202. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411(6837), 603-606 (2001).
203. Inohara N, Ogura Y, Fontalba A et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278(8), 5509-5512 (2003).
204. Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278(11), 8869-8872 (2003).
205. van Heel DA, Ghosh S, Butler M et al. Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur. J. Immunol. 35(8), 2471-2476 (2005).
206. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5(8), 800-808 (2004).
207. Netea MG, Hijmans A, van Wissen S et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur J. Clin. Invest. 34(2), 94-99 (2004).
208. Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn's disease is associated with a Toll-like receptor-9 polymorphism. Gastroenterology 127(1), 365-366 (2004).
209. Gewirtz AT, Vijay-Kumar M, Brant SR, Duerr RH, Nicolae DL, Cho JH. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 290(6), G1157-G1163 (2006).
210. McCarty DJ. Crystals and arthritis. Dis. Mon. 40(6), 255-299 (1994).
211. Bieber JD, Terkeltaub RA. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum. 50(8), 2400-2414 (2004).
212. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J. Immunol. 174(8), 5016-5023 (2005).
213. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 52(9), 2936-2946 (2005).
214. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440(7081), 237-241 (2006).
215. Ting JP, Kastner DL, Hoffman HM. CATERPILLERs, pyrin and hereditary immunological disorders. Nat. Rev. Immunol. 6(3), 183-195 (2006).
216. Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol. 14(21), 1929-1934 (2004).
217. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10(2), 417-426 (2002).
218. Mariathasan S, Newton K, Monack DM et al. Differential activation of the inflammasome by caspase-I adaptors ASC and Ipaf. Nature 430(6996), 213-218 (2004).